A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

被引：0
|
作者：
Sara M. Balch
Ines Vaz-Luis
Tianyu Li
Nabihah Tayob
Esha Jain
Karla Helvie
Jorge E. Buendia-Buendia
Erin Shannon
Steven J. Isakoff
Nadine M. Tung
Ian E. Krop
Nancy U. Lin
Nikhil Wagle
Rachel A. Freedman
机构：
[1] The Broad Institute of MIT and Harvard,Department of Data Sciences
[2] Department of Medical Oncology,undefined
[3] Dana-Farber Cancer Institute,undefined
[4] Institut Gustave Roussy,undefined
[5] Unit INSERM 981,undefined
[6] Dana-Farber Cancer Institute,undefined
[7] Massachusetts General Hospital,undefined
[8] Harvard Medical School,undefined
[9] Beth Israel Deaconess Medical Center,undefined
[10] Cellarity,undefined
[11] Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 189卷
关键词：
HER2+ breast cancer; Trastuzumab; Pertuzumab; Eribulin mesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：411 / 423
页数：12
相关论文
共 50 条
  • [1] A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer
    Balch, Sara M.
    Vaz-Luis, Ines
    Li, Tianyu
    Tayob, Nabihah
    Jain, Esha
    Helvie, Karla
    Buendia-Buendia, Jorge E.
    Shannon, Erin
    Isakoff, Steven J.
    Tung, Nadine M.
    Krop, Ian E.
    Lin, Nancy U.
    Wagle, Nikhil
    Freedman, Rachel A.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 411 - 423
  • [2] Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer
    Kawaguchi, Hidetoshi
    Yamashita, Toshinari
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Kawasoe, Teru
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
  • [3] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer
    Freedman, Rachel A.
    Luis, Ines Maria Vaz Duarte
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Galler, Sarah
    Sohl, Jessica
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
    Luis, Ines Maria Vaz Duarte
    Guo, Hao
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Gore, Danielle
    Andrews, Chelsea
    Osmani, Wafa
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] PRELIMINARY RESULTS OF PHASE I COMBINATION STUDY OF ERIBULIN MESYLATE WITH TRASTUZUMAB IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR 2 (HER2) POSITIVE ADVANCED OR METASTATIC BREAST CANCER
    Sasaki, Y.
    Miwa, K.
    Araki, K.
    Matsubara, N.
    Naito, Y.
    Obaishi, H.
    Namiki, M.
    Ishikawa, K.
    Mukai, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 152 - 152
  • [6] A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer (SONG-02)
    Abe, Hajime
    Kamigaki, Shunji
    Komoike, Yoshifumi
    Matsunami, Nobuki
    Nakano, Yoshiaki
    Tezuka, Kenji
    Tsurutani, Junji
    Yamamura, Jun
    Yamazaki, Keiichi
    CANCER RESEARCH, 2015, 75
  • [7] A phase I combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2-positive (HER2+) breast cancer
    Mukai, H.
    Shimada, K.
    Naito, Y.
    Matsubara, N.
    Nakanishi, T.
    Obaishi, H.
    Namiki, M.
    Narita, T.
    Masuda, M.
    Sasaki, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S414 - S414
  • [8] Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
    Hirofumi Mukai
    Toshiaki Saeki
    Ken Shimada
    Yoichi Naito
    Nobuaki Matsubara
    Tadashi Nakanishi
    Hiroshi Obaishi
    Masayuki Namiki
    Yasutsuna Sasaki
    Investigational New Drugs, 2015, 33 : 119 - 127
  • [9] Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
    Mukai, Hirofumi
    Saeki, Toshiaki
    Shimada, Ken
    Naito, Yoichi
    Matsubara, Nobuaki
    Nakanishi, Tadashi
    Obaishi, Hiroshi
    Namiki, Masayuki
    Sasaki, Yasutsuna
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 119 - 127
  • [10] Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)
    Toshinari Yamashita
    Hidetoshi Kawaguchi
    Norikazu Masuda
    Masahiro Kitada
    Kazutaka Narui
    Masaya Hattori
    Tetsuhiro Yoshinami
    Nobuki Matsunami
    Kazuhiro Yanagihara
    Teru Kawasoe
    Takeshi Nagashima
    Hiroko Bando
    Hiroshi Yano
    Yoshie Hasegawa
    Rikiya Nakamura
    Masahiro Kashiwaba
    Satoshi Morita
    Shinji Ohno
    Masakazu Toi
    Investigational New Drugs, 2021, 39 : 217 - 225
12345